Chesterbrook Firm Auxilium Lures New CFO From Nearby Endo

By

Andrew Saik (Image courtesy of www.bizjournals.com)
Andrew Saik (Image courtesy of www.bizjournals.com)

The wheeling and dealing isn’t done for Chesterbrook specialty biopharmaceutical firm Auxilium. Fresh off a $345 million merger with a Canadian ophthalmology biotech company, it has lured away the senior vice president of finance from Endo in Malvern.

Andrew Saik will become Auxilium’s new chief financial officer on Aug. 18, according to a Philadelphia Business Journal report.

Read more about the new hire and who he is replacing in the Philadelphia Business Journal here.

Tags: , , , , ,

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

Hidden
VT Yes
This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo

You Might Also Like

Rite AidPharma & Biotech

WSJ: Rite Aid Strikes Deal To Transfer Control Over To Creditors, Settle Opioid Claims

Katalin Karikó in her lab in 1989.Pharma & Biotech

Abington's Katalin Karikó's New Book Shares Her Journey from Rejection to COVID-19 Vaccine Hero

Endo headquarters.Pharma & Biotech

Endo International in Malvern to Pay $465M in Opioid Settlement

Researcher working with microplate panel for diseases diagnosis in the laboratory. Doctor working with microplatePharma & Biotech

Malvern-Based Venatorx Pharmaceuticals Expects Big News About Its Lead Antibiotic Candidate